Generally concerned about issues that effect medical innovation, including Medicare, Trade Issues, health care funding.
Duration: May 18, 2009
to
June 30, 2013
General Issues: Health Issues
Spending: about $660,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2009: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Joshua White
Government Relations
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2013
Rifkin, Livingston, Levitan & Silver, LLC terminated an engagement in which they represented PhRMA (on behalf of We Work for Health) on Jan. 3, 2014.
Original Filing: 300611227.xml
Lobbying Issues
Generally concerned about issues that effect medical innovation, including Medicare, Trade Issues, health care funding.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2013
In Q2, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on July 23, 2013.
Original Filing: 300586906.xml
Lobbying Issues
Generally concerned about issues that effect medical innovation, including Medicare, Trade Issues, health care funding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2013
In Q1, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on April 22, 2013.
Original Filing: 300561241.xml
Lobbying Issues
Advocating the importance and impact the biopharmacetical industry and medical innovation in general has on our economy. This includes jobs created through new medicines and access to medicine; as well as the indirect impact on construction and new techonologies related to medicial innovation. Trans-Pacific Partnership Act. Medicare Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2012
In Q4, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on Jan. 14, 2013.
Original Filing: 300543657.xml
Lobbying Issues
Advocating the importance and impact the biopharmacetical industry and medical innovation in general has on our economy. This includes jobs created through new medicines and access to medicine; as well as the indirect impact on construction and new techonologies related to medicial innovation. Trans-Pacific Partnership Act. Medicare.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on Oct. 23, 2012.
Original Filing: 300521649.xml
Lobbying Issues
Advocating the importance and impact the biopharmacetical industry and medical innovation in general has on our economy. This includes jobs created through new medicines and access to medicine; as well as the indirect impact on construction and new techonologies related to medicial innovation. 2012 Reauthorization of the Prescription Drug User Fee Act. Trans-Pacific Partnership Act. Medicare.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2012
In Q2, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on July 20, 2012.
Original Filing: 300495902.xml
Lobbying Issues
Advocating the importance and impact the biopharmacetical industry and medical innovation in general has on our economy. This includes jobs created through new medicines and access to medicine; as well as the indirect impact on construction and new techonologies related to medicial innovation. 2012 Reauthorization of the Prescription Drug User Fee Act. Trans-Pacific Partnership Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2012
In Q1, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on April 20, 2012.
Original Filing: 300472904.xml
Lobbying Issues
Advocating the importance and impact the biopharmacetical industry and medical innovation in general has on our economy. This includes jobs created through new medicines and access to medicine; as well as the indirect impact on construction and new techonologies related to medicial innovation. 2012 Reauthorization of the Prescription Drug User Fee Act. Trans-Pacific Partnership Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2011
In Q4, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on Jan. 19, 2012.
Original Filing: 300445522.xml
Lobbying Issues
Advocating the importance and impact the biopharmacetical industry and medical innovation in general has on our economy. This includes jobs created through new medicines and access to medicine; as well as the indirect impact on construction and new techonologies related to medicial innovation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on Oct. 20, 2011.
Original Filing: 300423181.xml
Lobbying Issues
Advocating the importance and impact the biopharmacetical industry and medical innovation in general has on our economy. This includes jobs created through new medicines and access to medicine; as well as the indirect impact on construction and new techonologies related to medicial innovation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on July 19, 2011.
Original Filing: 300404516.xml
Lobbying Issues
Advocating the importance and impact the biopharmacetical industry and medical innovation in general has on our economy. This includes jobs created through new medicines and access to medicine; as well as the indirect impact on construction and new techonologies related to medicial innovation. HR 1249 - America Invents Act - Patent Reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on April 20, 2011.
Original Filing: 300373342.xml
Lobbying Issues
Advocating the importance and impact the biopharmacetical industry and medical innovation in general has on our economy. This includes jobs created through new medicines and access to medicine; as well as the indirect impact on construction and new techonologies related to medicial innovation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2010
In Q4, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on Jan. 11, 2011.
Original Filing: 300356240.xml
Lobbying Issues
Advocating the importance and impact the biopharmacetical industry and medical innovation in general has on our economy. This includes jobs created through new medicines and access to medicine; as well as the indirect impact on construction and new techonologies related to medicial innovation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on Oct. 18, 2010.
Original Filing: 300316853.xml
Lobbying Issues
Advocating the importance and impact the biopharmacetical industry and medical innovation in general has on our economy. This includes jobs created through new medicines and access to medicine; as well as the indirect impact on construction and new techonologies related to medicial innovation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
In Q2, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on July 20, 2010.
Original Filing: 300302282.xml
Lobbying Issues
Advocating the importance and impact the biopharmacetical industry and medical innovation in general has on our economy. This includes jobs created through new medicines and access to medicine; as well as the indirect impact on construction and new techonologies related to medicial innovation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2010
In Q1, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on April 21, 2010.
Original Filing: 300276351.xml
Lobbying Issues
H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics;H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics;
S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Senator Max Baucus' "America's Healthy Future Act of 2009"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $50,000. The report was filed on Jan. 20, 2010.
Original Filing: 300241669.xml
Lobbying Issues
H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics;H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics;
S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
"America's Healthy Future Act of 2009"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
In Q3, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $40,000. The report was filed on Oct. 19, 2009.
Original Filing: 300214195.xml
Lobbying Issues
H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics;
H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics;
S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Senator Max Baucus' "America's Healthy Future Act of 2009"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, Rifkin, Livingston, Levitan & Silver, LLC lobbied for PhRMA (on behalf of We Work for Health) , earning $10,000. The report was filed on July 19, 2009.
Original Filing: 300188059.xml
Lobbying Issues
H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics;
S.726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
Rifkin, Livingston, Levitan & Silver, LLC filed a lobbying registration on June 24, 2009 to represent PhRMA (on behalf of We Work for Health), effective May 18, 2009.
Original Filing: 300171754.xml
Issue(s) they said they’d lobby about: Impact of medical innovation on the local economy and impact of Follow-on Biologic legislation on the pharmaceutical industry .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate